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Introduction {#ams2446-sec-0005}
============

Sepsis is defined as severe infection with organ dysfunction resulting from dysregulated host response; mortality from sepsis and septic shock remains high.[1](#ams2446-bib-0001){ref-type="ref"} Inflammatory responses to infection are enhanced by pathogen‐associated molecular pattern molecules, such as endotoxin, a lipopolysaccharide component of the outer membrane of Gram‐negative bacteria.[2](#ams2446-bib-0002){ref-type="ref"} Polymyxin B‐immobilized fiber column direct hemoperfusion (PMX‐DHP) can selectively adsorb endotoxin and theoretically prevent the progression or halt the sepsis cascade and decrease inflammatory humoral mediators.[3](#ams2446-bib-0003){ref-type="ref"}

The efficacy of PMX‐DHP has been evaluated in many studies, including three major randomized controlled trials, EUPHAS[4](#ams2446-bib-0004){ref-type="ref"} (early use of polymyxin B hemoperfusion in abdominal sepsis), ABDOMIX,[5](#ams2446-bib-0005){ref-type="ref"} and EUPHRATES[6](#ams2446-bib-0006){ref-type="ref"} (evaluation of polymyxin B hemoperfusion in a randomized controlled trial of adults with endotoxemia and septic shock), which nevertheless reported varying levels of efficacy in septic shock:[7](#ams2446-bib-0007){ref-type="ref"}, [8](#ams2446-bib-0008){ref-type="ref"} Polymyxin B‐immobilized fiber column direct hemoperfusion was associated with significant difference in 28‐day mortality in the EUPHAS trial and post hoc analysis of the EUPHRATES trial,[9](#ams2446-bib-0009){ref-type="ref"} but not in the ABDOMIX or EUPHRATES trials. The efficacy of PMX‐DHP in septic shock therefore remains controversial.

We propose that these variations could be explained by the timing of PMX‐DHP initiation and/or infection site. The first PMX‐DHP session was carried out within 24 h after abdominal surgery in the EUPHAS trial and within 12 h in the ABDOMIX trial. In the EUPHRATES trial, the mean time between randomization and intervention was 3.5 h, but no detailed PMX‐DHP initiation time is given. Regarding infection site, in the EUPHAS and ABDOMIX trials, patients with intra‐abdominal infection (IAI) were included, whereas, in the EUPHRATES trial, patients with high endotoxin activity assay (EAA) levels were included regardless of infection site: 35.2% with IAI and 35.9% with lung infection. The other studies also showed variations in patient groups and timing of PMX‐DHP initiation.[7](#ams2446-bib-0007){ref-type="ref"}

Our present study investigated the effects of PMX‐DHP on outcome in septic shock depending on initiation time and infection site (intra‐ versus extra‐abdominal).

Methods {#ams2446-sec-0006}
=======

Study cohort {#ams2446-sec-0007}
------------

The study was undertaken at the intensive care unit (ICU) of Shiga University of Medical Science Hospital (Otsu, Japan) from May 2010 to March 2015. Septic shock patients in the ICU receiving PMX‐DHP were eligible. Septic shock was defined according to the consensus definition of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee.[10](#ams2446-bib-0010){ref-type="ref"} We excluded patients younger than 18 years or who had undergone cardiac surgery or suffered cardiac arrest and also those not undergoing catecholamine treatment or i.v. fluid resuscitation with a bolus of 30 mL/kg within 3 h before PMX‐DHP initiation. Patients were divided into four groups according to the interval between catecholamine treatment and PMX‐DHP initiation, and further subdivided into two groups according to infection site, intra‐ or extra‐abdominal (IAI/EAI). The study was approved by the Shiga University of Medical Science institutional review board (approval no. 29‐167) and carried out in accordance with the principles of the Declaration of Helsinki (amended 2013). It was publicized by a protocol summary on the university website clearly informing of the patient\'s right to refuse participation.

Data collection {#ams2446-sec-0008}
---------------

The following data were retrieved: demographic information including: age, sex, and ICU admission route; pre‐existing conditions including hypertension, diabetes, chronic heart failure, chronic kidney disease, and hepatic cirrhosis; primary infection site and bacterial culture results; laboratory data including white blood cell count, C‐reactive protein, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, and lactate; vasopressor dose on PMX‐DHP initiation; and details of PMX‐DHP and continuous renal replacement therapy (CRRT), including time from catecholamine treatment to PMX‐DHP initiation, PMX‐DHP duration and frequency, and concomitant use of CRRT. Illness severity was assessed using Acute Physiology and Chronic Health Evaluation (APACHE) II, and the severity of organ dysfunction or failure was expressed by the Sequential Organ Failure Assessment (SOFA) score on ICU admission. The vasopressor agent dose was expressed as vasoactive--inotropic score (VIS),[11](#ams2446-bib-0011){ref-type="ref"} calculated as follows:

$$\text{VIS} = \text{dopamine\ dose}\,(\mu\text{g}/\text{kg}/\text{min}) + \text{dobutamine\ dose}\,(\mu\text{g}/\text{kg}/\text{min}) + 100 \times \text{epinephrine\ dose}\,(\mu\text{g}/\text{kg}/\text{min}) + 10 \times \text{milrinone\ dose}\,(\mu\text{g}/\text{kg}/\text{min}) + 10,000 \times \text{vasopressin\ dose}\,(\text{units}/\text{kg}/\text{min}) + 100 \times \text{norepinephrine\ dose}\,(\mu\text{g}/\text{kg}/\text{min})$$

Procedures {#ams2446-sec-0009}
----------

Polymyxin B‐immobilized fiber column direct hemoperfusion was carried out with an adsorbent column containing 5 mg polymyxin B per gram of polystyrene fiber (Toraymyxin; Toray Medical Co., Tokyo, Japan). The decision to initiate PMX‐DHP and CRRT was made by the responsible physicians after adequate fluid resuscitation and catecholamine support. A second PMX‐DHP was carried out only when the patient hemodynamics did not improve after the first PMX‐DHP and/or CRRT. Nafamostat mesilate was used as an anticoagulant at a dose adjusted to maintain an activated coagulation time of 180--200 s. Blood flow was set at 80--100 mL/min. The planned duration of PMX‐DHP was 24 h. We used a polymethyl methacrylate membrane hemofilter (CH‐1.8W or BG‐2.1PQ; Toray Medical Co.) or a polysulfone membrane hemofilter (AEF‐10; Asahi Kasei, Tokyo, Japan) for patients diagnosed with acute kidney injury based on the KDIGO classification,[12](#ams2446-bib-0012){ref-type="ref"} and an acrylonitrile‐co‐methallyl sulfonate surface‐treated membrane hemofilter (AN69ST; sepXiris150, Baxter Co., Tokyo, Japan) for non‐acute kidney injury patients.

Statistical analysis {#ams2446-sec-0010}
--------------------

Data are expressed as median with interquartile range for continuous variables or as number (%) for categorical variables. Continuous variables were compared between groups using the Mann--Whitney *U*‐test or Kruskal--Wallis test, and categorical variables using Pearson\'s χ^2^‐test or the Kruskal--Wallis test, as appropriate. The survival estimate was based on the Kaplan--Meier method and compared between groups using the log--rank test. We undertook univariate and multivariate logistic regression analyses (Enter method) to evaluate the association of 90‐day mortality with the interval from catecholamine treatment to PMX‐DHP initiation. Variables considered were age, APACHE II score, and whether the patient underwent emergency surgery or drainage. A *P*‐value of \<0.05 was considered statistically significant for all comparisons. Statistical analyses were undertaken using [spss]{.smallcaps} 22 (SPSS, Chicago, IL, USA).

Results {#ams2446-sec-0011}
=======

The study enrolled 62 patients during the observation period. The final 49 eligible patients were categorized into four groups of 12 or 13 each by quartile of interval (Fig. [1](#ams2446-fig-0001){ref-type="fig"}). The median interval from catecholamine treatment to PMX‐DHP initiation was 9 h (interquartile range, 6--29 h).

![Outline of all study participants. Study flowchart of patients with septic shock based on the interval between catecholamine treatment and initiation of direct hemoperfusion with polymyxin B‐immobilized fiber column (PMX‐DHP).](AMS2-7-e446-g001){#ams2446-fig-0001}

Table [1](#ams2446-tbl-0001){ref-type="table"} presents baseline clinical characteristics. The four groups showed no significant difference in age, SOFA score, APACHE II score, or pre‐existing conditions, but did differ in the interval between catecholamine treatment and PMX‐DHP initiation (*P* \< 0.001). In the 90‐day survival curves in Figure [2](#ams2446-fig-0002){ref-type="fig"}, significant differences were noted between groups 1, 2, 3, and 4 in 90‐day mortality (8.3%, 46.1%, 58.3%, and 75.0%, respectively; *P *=* *0.021). The results of univariate and multivariate analyses are shown in Table [2](#ams2446-tbl-0002){ref-type="table"}. The interval from catecholamine treatment to PMX‐DHP initiation and APACHE II score were correlated with 90‐day mortality (odds ratio 1.060, 1.117; 95% confidence interval \[CI\], 1.004--1.117, 1.021--1.221; *P *=* *0.028, 0.015; Table [2](#ams2446-tbl-0002){ref-type="table"}). Table [1](#ams2446-tbl-0001){ref-type="table"} shows differences in infection site and organism between the four groups. Specifically, the number of patients with lung infection was lower in group 1 (groups 1, 2, 3 and 4: 8.3%, 30.6%, 33.3%, and 25.0%, respectively). To assess the resulting impact on the efficacy of early PMX‐DHP initiation, we divided the patients into two groups according to infection site, intra‐ or extra‐abdominal, and evaluated the efficacy of early PMX‐DHP initiation in each group.

###### 

Characteristics of four groups of patients with septic shock

                                                                Group 1                Group 2                Group 3                Group 4                *P*‐value
  ------------------------------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- -----------
  Number of patients                                            12                     13                     12                     12                      
  Age, years                                                    73.5 (65.2--78.7)      74.0 (64.5--78.0)      67.5 (41.0--78.0)      74.0 (68.0--80.5)      0.534
  Sex, male; *n* (%)                                            8 (66.6)               8 (61.5)               7 (58.3)               7 (58.3)               0.973
  Height, cm                                                    164.5 (159.7--171.8)   161.9 (160.6--170.0)   164.0 (157.2--171.3)   159.5 (155.0--166.5)   0.346
  Weight, kg                                                    63.6 (53.0--68.8)      56.2 (45.3--61.4)      48.5 (42.7--61.4)      53.7 (46.7--66.9)      0.490
  Time from catecholamine initiation to PMX‐DHP initiation, h   3.5 (2.0--5.3)         8.0 (6.1--8.7)         18.0 (14.0--21.0)      46 (31.1--82.0)        \<0.001\*
  APACHE II score                                               22 (16.0--33.0)        27.0 (18.0--34.5)      24.0 (20.7--30.7)      29.0 (19.2--39.2)      0.301
  SOFA score                                                    12.5 (11.2--16.0)      14.0 (11.5--15.5)      9.5 (7.5--14.0)        14.5 (11.2--17.0)      0.181
  PaO~2~/FiO~2~                                                 121.0 (118.2--261.6)   125.0 (84.1--210.5)    114.5 (70.0--279.5)    114.0 (91.0--192.9)    0.349
  WBC, ×10^3^/μL                                                9.8 (4.4--29.8)        6.7 (1.1--11.4)        8.0 (1.3--15.2)        6.9 (2.5--18.2)        0.422
  CRP, mg/dL                                                    12.2 (3.9--16.6)       16.7 (4.5--23.0)       15.3 (9.9--19.9)       13.6 (4.3--18.5)       0.578
  HR, b.p.m.                                                    121.0 (97.2--142)      106.0 (93.5--121.5)    110 (101.7--130.7)     114.5 (88.2--135)      0.784
  MAP, mmHg                                                     67.0 (57.5--82.0)      70.6 (54.5--85.5)      69.1 (62.5--81.1)      74.0 (50.6--84.4)      0.978
  Lactate on PMX‐DHP initiation, mg/dL                          26.0 (20--83.0)        27.0 (18.0--40.0)      34.0 (20.0--72.0)      45.0 (16.0--73.0)      0.616
  VIS on PMX‐DHP initiation                                     15.4 (7.0--28.8)       23.0 (13.5--47.7)      21.0 (10.1--25.8)      28.0 (14.2--36.8)      0.385
  Concomitant use of CRRT, *n* (%)                              12 (100.0)             13 (100.0)             11 (91.6)              11 (91.6)              0.546
  Duration of PMX‐DHP, h                                        17.0 (9.2--23.0)       11.0 (7.4--19.5)       13.5 (9.1--20.2)       18.5 (9.5--24.0)       0.684
  Two sessions of PMX‐DHP, *n* (%)                              2 (16.6)               0 (0.0)                2 (16.6)               0 (0.0)                0.217
  Initiation of PMX‐DHP before CRRT, *n* (%)                    7 (58.3)               5 (38.4)               6 (50.0)               1 (8.3)                0.069
  Underwent emergency surgery or drainage, *n* (%)              5 (41.6)               6 (46.1)               3 (25)                 3 (25)                 0.373
  Admission route to ICU, *n* (%)                                                                                                                           
  Emergency department                                          4 (33.0)               5 (38.4)               2 (16.6)               2 (16.6)               0.942
  Other hospital                                                1 (8.3)                1 (7.6)                3 (25.0)               4 (33.3)               
  Hospital ward                                                 7 (58.3)               7 (53.8)               7 (58.3)               6 (50.0)               
  Organism                                                                                                                                                  
  *Escherichia coli*                                            3                      3                      3                      1                       
  *Enterococcus* spp.                                           2                      2                      0                      4                       
  *Klebsiella* spp.                                             1                      3                      3                      1                       
  *Streptococcus* spp.                                          3                      2                      1                      0                       
  MRSA                                                          0                      1                      1                      1                       
  *Pseudomonas* spp.                                            1                      1                      0                      0                       
  *Aeromonas* spp.                                              0                      0                      1                      0                       
  *Proteus* spp.                                                1                      0                      0                      0                       
  *Prevotella* spp.                                             1                      0                      0                      0                       
  *Haemophilus influenzae*                                      0                      1                      0                      0                       
  *Enterobacter* spp.                                           0                      1                      0                      0                       
  *Stenotrophomonas maltophilia*                                0                      0                      1                      1                       
  Unknown                                                       0                      2                      2                      4                       
  Site                                                                                                                                                      
  Abdomen                                                       7                      8                      6                      8                       
  Lung                                                          1                      4                      4                      3                       
  Urinary tract                                                 2                      0                      0                      1                       
  Mediastinum                                                   1                      0                      0                      0                       
  Central nervous system                                        1                      0                      1                      0                       
  Blood                                                         0                      1                      0                      0                       
  Soft tissue                                                   0                      0                      1                      0                       

Data are presented as the median (first quartile to third quartile) or number (%). \**P* \< 0.05.

APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C‐reactive protein; CRRT, continuous renal replacement therapy; HR, heart rate; ICU, intensive care unit; MAP, mean arterial pressure; MRSA, Methicillin‐resistant *Staphylococcus aureus*; PMX‐DHP, direct hemoperfusion with polymyxin B‐immobilized fiber column; SOFA, Sequential Organ Failure Assessment; VIS, vasoactive--inotropic score; WBC, white blood cell.

John Wiley & Sons, Ltd

![Survival of all study participants with septic shock. Kaplan--Meier survival curves according to the interval between catecholamine treatment and initiation of direct hemoperfusion with polymyxin B‐immobilized fiber column. Group 1, \<6 h; group 2, 6--9 h; group 3, 9--29 h; and group 4, \>29 h.](AMS2-7-e446-g002){#ams2446-fig-0002}

###### 

Risk factors related to 90‐day mortality in 49 patients with septic shock

  Item                                                          Univariate analysis   *P*‐value      Multivariate analysis   *P*‐value                  
  ------------------------------------------------------------- --------------------- -------------- ----------------------- ----------- -------------- -------
  Age (years)                                                   1.034                 0.986--1.085   0.169                   1.033       0.978--1.090   0.251
  APACHE II score                                               1.113                 1.034--1.197   0.004                   1.117       1.021--1.221   0.015
  Underwent emergency surgery or drainage (yes/no)              2.424                 0.725--8.133   0.150                   0.709       0.282--6.434   0.709
  Time from catecholamine treatment to PMX‐DHP initiation (h)   1.061                 1.012‐1.112    0.014                   1.060       1.004‐1.117    0.028

APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; PMX‐DHP, direct hemoperfusion with polymyxin B‐immobilized fiber column.

John Wiley & Sons, Ltd

Given the median interval of 9 h from catecholamine treatment to PMX‐DHP initiation, we divided the 29 IAI patients into an early group (within 9 h, *n* = 15) and a late group (\>9 h, *n* = 14) (Fig. [3](#ams2446-fig-0003){ref-type="fig"}). No significant intergroup differences in age, SOFA score, APACHE II score, or pre‐existing conditions were noted (Table [3](#ams2446-tbl-0003){ref-type="table"}), but the total number of patients undergoing emergency operation or drainage did differ significantly (*P *=* *0.034). In the 90‐day survival curves in Figure [4](#ams2446-fig-0004){ref-type="fig"}A, the early group had significantly lower 90‐day mortality (13.3% versus 64.2%; *P *=* *0.003).The results of univariate and multivariate analyses are shown in Table [4](#ams2446-tbl-0004){ref-type="table"}. The interval from catecholamine treatment to PMX‐DHP initiation was associated with 90‐day mortality (odds ratio 1.058; 95% CI, 1.000--1.119; *P *=* *0.049) (Table [4](#ams2446-tbl-0004){ref-type="table"}).

![Enrollment of patients with intra‐abdominal infection and extra‐abdominal infection. Study flowchart of patients with septic shock based on the infection site and the interval between catecholamine treatment and initiation of direct hemoperfusion with polymyxin B‐immobilized fiber column (PMX‐DHP).](AMS2-7-e446-g003){#ams2446-fig-0003}

###### 

Characteristics of two groups of patients with intra‐abdominal infection and extra‐abdominal infection

                                                                Intra‐abdominal infection   Extra‐abdominal infection                                                             
  ------------------------------------------------------------- --------------------------- --------------------------- ----------- ---------------------- ---------------------- -----------
  Number of patients                                            15                          14                                      10                     10                      
  Age, years                                                    74.0 (65.0--78.0)           75.5 (66.7--81.2)           0.505       73.5 (63.7--78.7)      67.0 (53.0--75.2)      0.19
  Sex, male; *n* (%)                                            10 (66.6)                   7 (50.0)                    0.362       6 (60.0)               7 (70.0)               0.639
  Height, cm                                                    165.0 (159.6--172.3)        161.2 (153.7--169.6)        0.4         162.7 (156.2--166.2)   160.0 (156.7--168.1)   1
  Weight, kg                                                    56.7 (51.8--64.7)           53.7 (44.8--63.8)           0.451       61.6 (41.9--66.2)      47.9 (45.3--63.6)      0.631
  Time from catecholamine initiation to PMX‐DHP initiation, h   6.0 (4.0--8.0)              29.0 (18.5--60.7)           \<0.001\*   5.8 (3.0--8.6)         21.0 (14.6--44.0)      \<0.001\*
  APACHE II score                                               19.0 (16.0--24.0)           23.5 (18.5--31.0)           0.201       29.5 (19.2--38.0)      31.0 (23.0--40.2)      0.739
  SOFA score                                                    12.0 (12.0--16.0)           13 (9.7--16.2)              0.914       14.0 (11.0--16.2)      12.6 (9.0--15.5)       0.353
  PaO~2~/FiO~2~                                                 170.4 (125.0--267.8)        120.5 (98.0--295.5)         0.715       106.5 (91.5--178.0)    108.5 (86.5--133.0)    0.481
  WBC, ×10^3^/μL                                                7.3 (3.9--17.1)             9.0 (3.1--17.0)             0.914       7.4 (1.0--17.9)        6.8 (0.3--14.2)        0.579
  CRP, mg/dL                                                    14.1 (7.0--17.5)            13.3 (5.3--17.0)            0.780       11.4 (2.8--22.1)       15.9 (10.3--21.9)      0.529
  HR, b.p.m.                                                    106.0 (96.0--137.0)         110.5 (100.2--133.2)        0.533       115.0 (97.0--133.7)    115.0 (86.5--95.7)     0.971
  MAP, mmHg                                                     70.3 (57.3--85.6)           79.0 (61.9--87.5)           0.813       68.8 (51.5--72.9)      68.8 (51.5--73.1)      0.912
  Lactate on PMX‐DHP initiation, mg/dL                          27.5 (16.7--47.2)           66.5 (29.7--102.0)          0.074       23.5 (20.0--72.2)      27.0 (12.5--50.0)      0.673
  VIS on PMX‐DHP initiation                                     15.7 (6.0--28.9)            22.5 (10.5--30.2)           0.425       24.4 (16.3--37.0)      23.0 (11.8--32.1)      0.529
  Concomitant use of CRRT, *n* (%)                              15 (100.0)                  13 (92.8)                   0.292       10 (100.0)             9 (90.0)               0.305
  Duration of PMX‐DHP, h                                        15.0 (9.0--22.0)            18 (10.3--24.0)             0.652       14.0 (7.4--18.5)       13.5 (9.0--23.1)       0.684
  Two sessions of PMX‐DHP, *n* (%)                              2 (13.3)                    2 (14.2)                    0.941       0 (0.0)                0 (0.0)                 
  Initiation of PMX‐DHP before CRRT, *n* (%)                    11 (73.3)                   5 (35.7)                    0.042\*     1 (10.0)               2 (20.0)               0.531
  Underwent emergency surgery or drainage, *n* (%)              12 (80.0)                   6 (42.5)                    0.034\*     0 (0.0)                0 (0.0)                 
  Admission route to ICU, *n* (%)                                                                                                                                                 
  Emergency department                                          4 (26.6)                    4 (28.5)                    0.156       5 (50.0)               0 (0.0)                0.014\*
  Other hospital                                                1 (6.6)                     6 (42.8)                    1 (10.0)    1 (10.0)                                      
  Hospital ward                                                 10 (66.6)                   4 (28.5)                    4 (40.0)    9 (90.0)                                      
  Organism                                                                                                                                                                        
  *Escherichia coli*                                            4                           4                                       2                      0                       
  *Enterococcus* spp.                                           4                           4                                       0                      0                       
  *Klebsiella* spp.                                             2                           1                                       2                      3                       
  *Streptococcus* spp.                                          1                           0                                       4                      1                       
  MRSA                                                          0                           0                                       1                      3                       
  *Pseudomonas* spp.                                            2                           0                                       0                      0                       
  *Aeromonas* spp.                                              0                           1                                       0                      0                       
  *Proteus* spp.                                                0                           0                                       1                      0                       
  *Prevotella* spp.                                             1                           0                                       0                      0                       
  *Haemophilus influenzae*                                      0                           0                                       1                      0                       
  *Enterobacter* spp.                                           1                           0                                       0                      0                       
  *Stenotrophomonas maltophilia*                                0                           1                                       0                      1                       
  Unknown                                                       1                           4                                       1                      2                       
  Site                                                                                                                                                                            
  Abdomen                                                       15                          14                                      0                      0                       
  Lung                                                          0                           0                                       5                      7                       
  Urinary tract                                                 0                           0                                       2                      1                       
  Mediastinum                                                   0                           0                                       1                      0                       
  Central nervous system                                        0                           0                                       1                      1                       
  Blood                                                         0                           0                                       1                      0                       
  Soft tissue                                                   0                           0                                       0                      1                       

Data are presented as the median (first quartile to third quartile) or number (percentage). \**P* \< 0.05.

APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C‐reactive protein; CRRT, continuous renal replacement therapy; HR, heart rate; ICU, intensive care unit; MAP, mean arterial pressure; MRSA, Methicillin‐resistant *Staphylococcus aureus*; PMX‐DHP, direct hemoperfusion with polymyxin B‐immobilized fiber column; SOFA, Sequential Organ Failure Assessment; VIS, vasoactive--inotropic score; WBC, white blood cell.

John Wiley & Sons, Ltd

###### 

Risk factors related to 90‐day mortality in patients with intra‐abdominal infection (IAI) or extra‐abdominal infection (EAI)

  Item                                                          Univariate analysis   *P*‐value      Multivariate analysis   *P‐*value                  
  ------------------------------------------------------------- --------------------- -------------- ----------------------- ----------- -------------- -------
  Patients with IAI                                                                                                                                     
  Age (years)                                                   1.064                 0.978--1.158   0.148                   1.057       0.961--1.164   0.254
  APACHE II score                                               1.054                 0.959--1.159   0.274                   1.042       0.927--1.172   0.489
  Underwent emergency surgery or drainage (yes/no)              0.600                 0.129--2.796   0.515                   0.772       0.069--5.707   0.772
  Time from catecholamine treatment to PMX‐DHP initiation (h)   1.062                 1.004--1.124   0.036                   1.058       1.000--1.119   0.049
  Patients with EAI                                                                                                                                     
  Age (years)                                                   1.027                 0.958--1.100   0.456                   1.044       0.949--1.148   0.376
  APACHE II score                                               1.213                 1.025--1.436   0.025                   1.230       1.005--1.505   0.045
  Time from catecholamine treatment to PMX‐DHP initiation (h)   1.073                 0.972--1.186   0.163                   1.119       0.936--1.338   0.217

APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; PMX‐DHP, direct hemoperfusion with polymyxin B‐immobilized fiber column.

John Wiley & Sons, Ltd

![Survival study of patients with intra‐abdominal infection (IAI) and extra‐abdominal infection (EAI). Kaplan--Meier survival curves according to the infection site and the interval between catecholamine treatment and initiation of direct hemoperfusion with polymyxin B‐immobilized fiber column. A, IAI group (*n* = 29): early group (within 9 h) and late group (\>9 h). B, EAI group (*n* = 20): early group (within 9 h) and late group (\>9 h).](AMS2-7-e446-g004){#ams2446-fig-0004}

Given the median interval of 9 h from catecholamine treatment to PMX‐DHP initiation, we divided the 20 EAI patients (Figure [3](#ams2446-fig-0003){ref-type="fig"}) into an early (within 9 h, *n* = 10) and a late group (\>9 h, *n* = 10). No significant intergroup differences in age, SOFA score, APACHE II score, or pre‐existing conditions were noted (Table [2](#ams2446-tbl-0002){ref-type="table"}). In the 90‐day survival curves in Figure [4](#ams2446-fig-0004){ref-type="fig"}B, the two groups had similar 90‐day mortality (50.0% versus 70.0%; *P *=* *0.564), and the interval from catecholamine treatment to PMX‐DHP initiation was not associated with 90‐day mortality (odds ratio 1.119; 95% CI, 0.936--1.338; *P *=* *0.217) (Table [4](#ams2446-tbl-0004){ref-type="table"}).

Discussion {#ams2446-sec-0012}
==========

Previous studies of the timing of PMX‐DHP initiation have reported that early initiation could reduce mortality in septic shock patients or reduce catecholamine requirement.[13](#ams2446-bib-0013){ref-type="ref"}, [14](#ams2446-bib-0014){ref-type="ref"} However, there have been no reports that differentiated according to infection site (IAI/EAI) and evaluated the effectiveness of early PMX‐DHP initiation. Our results suggested that initiation of PMX‐DHP therapy within 9 h after catecholamine treatment produces a survival benefit in septic shock with IAI.

First, we divided all study patients into four groups according to the interval between catecholamine treatment and PMX‐DHP initiation and we noted the efficacy of early initiation (Fig. [2](#ams2446-fig-0002){ref-type="fig"}). However, although the proportion of abdominal infection patients was similar in all four groups, the number of patients with lung infection was lower in group 1 than other groups, and the number who had undergone emergency surgery or drainage was lower in groups 1 and 2 than groups 3 and 4. We therefore assumed that infection site correlated with different group characteristics, such as SOFA score, catecholamine requirement (VIS), and organisms, and proposed that these differences influenced the efficacy of early PMX‐DHP initiation. We therefore divided the patients into two groups according to infection site, intra‐ or extra‐abdominal, and evaluated the efficacy of early initiation in each group. This subanalysis showed that early PMX‐DHP initiation produces a survival benefit in septic shock with IAI, suggesting that a differentiation by infection site, especially IAI and EAI, is necessary when considering the effect of PMX‐DHP.

One possible explanation for the effect of early PMX‐DHP initiation in septic shock could be catecholamine reduction due to PMX‐DHP. Table [1](#ams2446-tbl-0001){ref-type="table"} shows that VIS on PMX‐DHP initiation in group 1 was lower than in other groups. We therefore compared the reduction in catecholamine between groups and found that the amount of decrease was greater in the early than in the late group, but not to a statistically significant extent (mean ΔVIS = VIS on PMX‐DHP initiation − VIS after 24 h). All patients: group 1, 4.0; group 2, −2.2; group 3, 2.0; group 4, 1.0; *P *=* *0.618. In IAI patients: early group, 3.3; late group, 1.0; *P *=* *0.085. In EAI patients: early group, 2.6; late group, −2.3; *P *=* *0.436. Similarly, APACHE II score in the early group was lower, but not significantly so (Table [1](#ams2446-tbl-0001){ref-type="table"}). We therefore carried out univariate and multivariate logistic regression analyses and found that early PMX‐DHP initiation was significantly associated with 90‐day mortality (Tables [3](#ams2446-tbl-0003){ref-type="table"} and [4](#ams2446-tbl-0004){ref-type="table"}). These results suggest that reduction of catecholamine might help to prevent organ failure, resulting in reduced mortality.

Another possible explanation is endotoxin tolerance of monocytes. Previous research has established that the function of a monocyte shifts from a pro‐inflammatory to an immunosuppressive phenotype within a few hours after exposure to lipopolysaccharide.[15](#ams2446-bib-0015){ref-type="ref"}, [16](#ams2446-bib-0016){ref-type="ref"} Based on these data, we propose that initiation of PMX‐DHP before development of endotoxin tolerance could be the most effective strategy to control endotoxin and inflammatory mediators.

The survival rate in the present study was somewhat higher than in other studies. A possible explanation is PMX‐DHP duration. In previous randomized controlled trials, the target duration for each PMX‐DHP was 2 h. In our ICU, PMX‐DHP was typically given in one session for 24 h. Recent research suggests that PMX‐DHP is able to adsorb endotoxin for longer than 2 h[17](#ams2446-bib-0017){ref-type="ref"} and that prolonged PMX‐DHP treatment is effective in improving hemodynamics in severe sepsis or septic shock.[18](#ams2446-bib-0018){ref-type="ref"}, [19](#ams2446-bib-0019){ref-type="ref"} Taken together with our data, this indicates that early initiation and prolonged treatment could influence PMX‐DHP efficacy in septic shock.

A possible reason for the absence of a survival benefit from early PMX‐DHP initiation in septic shock with EAI could be patient selection and/or use of a single session of PMX‐DHP. There could have been fewer patients with endotoxemia who benefited from PMX‐DHP among the EAI patients than among the IAI patients. Indeed, in the present study, the number of cases with Gram‐positive bacteria was higher among the former (40.9% versus 29.0%). Marshall *et al*. showed that endotoxin levels were also increased in cases involving Gram‐positive infections.[20](#ams2446-bib-0020){ref-type="ref"} It was difficult to distinguish the EAI patients with endotoxemia in the present study as EAA was not measured. Another possible reason for the lack of improved outcome is that EAI patients might need two PMX‐DHP sessions. The catecholamine requirement (median VIS) at 24 h after PMX‐DHP initiation was 10.0 in IAI patients and 21.0 in EAI patients, suggesting that a single PMX‐DHP session is insufficient to improve hemodynamics in EAI patients. Two PMX‐DHP sessions might offer a survival benefit in EAI patients and this possibility needs further investigation.

Several limitations of the present study need to be considered. First, the retrospective design and small number of patients limited its power. Given the retrospective design, it is possible that the early PMX‐DHP initiation group included patients who would have improved without PMX‐DHP and that the late initiation group included patients who had failed to respond to any prior treatment. These factors could cause a large survival bias. Our results therefore indicate only a possible association between early PMX‐DHP initiation and mortality in septic shock. A larger‐scale study on adaptive patients over an appropriate period is therefore needed to clarify whether early PMX‐DHP initiation of PMX‐DHP has a measurable survival benefit in septic shock. Second, the study groups differed in terms of certain baseline characteristics, such as lactate level on PMX‐DHP initiation and admission route. These differences are likely to be associated with the interval between catecholamine treatment and PMX‐DHP initiation. Patients from hospital wards received operation or PMX‐DHP promptly, but patients from other hospitals experienced a delay and therefore had a higher lactate level at PMX‐DHP initiation. Moreover, within the IAI group, there were significant differences in the number of patients undergoing emergency operation or drainage, but no significant difference in illness severity as measured by APACHE II and SOFA scores. Finally, we were unable to determine the exact time of sepsis onset retrospectively. For study purposes, we took the time of catecholamine treatment as the basis. The study nevertheless showed that, when using PMX‐DHP, the timing of initiation is important. Specifically, PMX‐DHP should be initiated as soon as possible after sepsis is diagnosed.

Conclusions {#ams2446-sec-0013}
===========

Early initiation of PMX‐DHP (within 9 h after catecholamine treatment) was effective in improving clinical outcome in septic shock due to IAI.
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